|
US5863560A
(en)
*
|
1996-09-11 |
1999-01-26 |
Virotex Corporation |
Compositions and methods for topical application of therapeutic agents
|
|
US20030157036A1
(en)
*
|
2002-02-20 |
2003-08-21 |
Osborne David W. |
Topical dapsone for the treatment of acne
|
|
US6787157B1
(en)
*
|
1998-03-10 |
2004-09-07 |
Abbott Laboratories |
Multiphase active ingredient-containing formulations
|
|
US6294188B1
(en)
|
1998-07-09 |
2001-09-25 |
Aviana Biopharm Inc. |
Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
|
|
KR20020043455A
(ko)
*
|
2000-01-31 |
2002-06-10 |
콜로보라티브 테크놀러지스 인코포레이티드 |
주문형 개인화 화장품 및 약제 제제 생산 방법 및 시스템
|
|
US20040092494A9
(en)
*
|
2000-08-30 |
2004-05-13 |
Dudley Robert E. |
Method of increasing testosterone and related steroid concentrations in women
|
|
US6503894B1
(en)
*
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
|
US20040002482A1
(en)
*
|
2000-08-30 |
2004-01-01 |
Dudley Robert E. |
Androgen pharmaceutical composition and method for treating depression
|
|
US20020193321A1
(en)
*
|
2000-12-12 |
2002-12-19 |
Mohan Vishnupad |
Dual dispenser for aesthitically acceptable delivery of anhydrous skin treatment compositions
|
|
US6495596B1
(en)
|
2001-03-23 |
2002-12-17 |
Biozibe Laboratories, Inc. |
Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
|
|
US6998421B2
(en)
|
2001-06-07 |
2006-02-14 |
Biozone Laboratories, Inc. |
Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
|
|
US6475526B1
(en)
|
2001-06-05 |
2002-11-05 |
Jeffrey B. Smith |
Zinc containing compositions for anti-viral use
|
|
US20040072810A1
(en)
|
2001-11-07 |
2004-04-15 |
Besins International Belgique |
Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
|
|
US20030144362A1
(en)
*
|
2002-01-28 |
2003-07-31 |
Utterberg David S. |
High viscosity antibacterials for cannulae
|
|
US20050042240A1
(en)
*
|
2002-01-28 |
2005-02-24 |
Utterberg David S. |
High viscosity antibacterials
|
|
WO2003092704A1
(fr)
*
|
2002-04-30 |
2003-11-13 |
Mochida Pharmaceutical Co., Ltd. |
Preparation externe de vidarabine a propriete systemique amelioree
|
|
US20040086469A1
(en)
*
|
2002-10-30 |
2004-05-06 |
Osborne David W. |
Protectant for UV-induced skin damage
|
|
US6855341B2
(en)
*
|
2002-11-04 |
2005-02-15 |
Jeffrey B. Smith |
Anti-viral compositions and methods of making and using the anti-viral compositions
|
|
US20080274209A1
(en)
*
|
2002-11-04 |
2008-11-06 |
Integritas Pharma, Inc. |
Methods of treating inflammation
|
|
JP4591746B2
(ja)
*
|
2002-12-03 |
2010-12-01 |
大正製薬株式会社 |
難溶性抗ウイルス成分含有水溶性外用剤組成物
|
|
WO2004105662A1
(en)
*
|
2003-05-23 |
2004-12-09 |
Program For Appropriate Technology In Health |
Microbicidal compositions and methods of use
|
|
US7186416B2
(en)
*
|
2003-05-28 |
2007-03-06 |
Stiefel Laboratories, Inc. |
Foamable pharmaceutical compositions and methods for treating a disorder
|
|
US20060229258A1
(en)
*
|
2003-07-30 |
2006-10-12 |
Daniela Serikaku |
Steroidal compositions containing hydroxycarboxylic acids and methods of using the same
|
|
US20060204526A1
(en)
*
|
2003-08-13 |
2006-09-14 |
Lathrop Robert W |
Emulsive composition containing Dapsone
|
|
MXPA06001713A
(es)
*
|
2003-08-13 |
2007-01-26 |
Qlt Usa Inc |
Composicion de emulsion que contiene dapsone.
|
|
US20050191338A1
(en)
*
|
2004-01-30 |
2005-09-01 |
Lifeng Kang |
Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
|
|
WO2006004759A2
(en)
*
|
2004-06-29 |
2006-01-12 |
Mcclellan Stephanie N |
Topical compositions for anti-aging
|
|
US20060024372A1
(en)
*
|
2004-07-29 |
2006-02-02 |
Utterberg David S |
High viscosity antibacterials
|
|
WO2006036936A2
(en)
*
|
2004-09-27 |
2006-04-06 |
Bridge Pharma, Inc. |
The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
|
|
WO2006037047A2
(en)
*
|
2004-09-27 |
2006-04-06 |
Bridge Pharma, Inc. |
The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
|
|
KR101150242B1
(ko)
|
2004-10-27 |
2012-06-13 |
유니버시티 오브 덴버 |
부신피질 자극 호르몬 유사체 및 관련 방법
|
|
US20070088012A1
(en)
*
|
2005-04-08 |
2007-04-19 |
Woun Seo |
Method of treating or preventing type-2 diabetes
|
|
JP2008536937A
(ja)
*
|
2005-04-20 |
2008-09-11 |
ザイロス コーポレイション |
経皮薬物送達系に用いる微生物セルロース材料、製造および使用方法
|
|
US20060271262A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Mclain Harry P Iii |
Wireless agricultural network
|
|
US8389469B2
(en)
*
|
2005-06-06 |
2013-03-05 |
The Rockefeller University |
Bacteriophage lysins for Bacillus anthracis
|
|
US20100154146A1
(en)
|
2008-07-02 |
2010-06-24 |
S.C. Johnson & Son, Inc. |
Carpet decor and setting solution compositions
|
|
US8846154B2
(en)
|
2005-06-07 |
2014-09-30 |
S.C. Johnson & Son, Inc. |
Carpet décor and setting solution compositions
|
|
US7582291B2
(en)
*
|
2005-06-30 |
2009-09-01 |
The Rockefeller University |
Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
|
|
ITMI20051417A1
(it)
*
|
2005-07-22 |
2007-01-23 |
Mipharm S P A |
Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
|
|
US20090176743A1
(en)
*
|
2005-07-29 |
2009-07-09 |
Priscilla Schaffer |
Methods for treating or preventing reactivation of a latent herpesvirus infection
|
|
WO2007024628A2
(en)
|
2005-08-24 |
2007-03-01 |
The Rockefeller University |
Ply-gbs mutant lysins
|
|
US20070071705A1
(en)
*
|
2005-09-29 |
2007-03-29 |
De Oliveira Monica A M |
Topical anti-microbial compositions
|
|
PT1937276E
(pt)
|
2005-10-12 |
2013-02-21 |
Besins Healthcare Luxembourg |
Gel de testosterona melhorado e método para a sua utilização
|
|
JP2007320886A
(ja)
*
|
2006-05-31 |
2007-12-13 |
Isp Japan Kk |
含水ゲル状シート剤及びその製造方法
|
|
WO2008011161A2
(en)
*
|
2006-07-21 |
2008-01-24 |
Bridge Pharma, Inc. |
Dermal anesthetic compounds
|
|
CA2714674A1
(en)
|
2008-02-27 |
2009-09-03 |
John Steven Garrett |
Dapsone to treat rosacea
|
|
US20100029781A1
(en)
*
|
2008-06-04 |
2010-02-04 |
Morris Jerome A |
Methods for preparation of anti-acne formulation and compositions prepared thereby
|
|
JP5732397B2
(ja)
|
2008-10-10 |
2015-06-10 |
ルソメディカメンタ, エス.エー.Lusomedicamenta, S.A. |
抗菌性ファージペプチド及びその使用法
|
|
BRPI1008663B8
(pt)
|
2009-02-06 |
2021-10-05 |
Technophage Investig E Desenvolvimento Em Biotecnologia S A |
bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago
|
|
US20110117182A1
(en)
*
|
2009-07-30 |
2011-05-19 |
Allergan, Inc. |
Combination of dapsone with other anti-acne agents
|
|
US8999302B1
(en)
|
2009-10-22 |
2015-04-07 |
Aplicare, Inc. |
Skin dye protectant formulations
|
|
PT104837A
(pt)
|
2009-11-24 |
2011-05-24 |
Technophage Investiga O E Desenvolvimento Em Biotecnologia S A |
P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
|
|
MX2012010684A
(es)
|
2010-03-17 |
2012-11-06 |
Novaliq Gmbh |
Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
|
|
EP3789031B1
(en)
|
2010-09-17 |
2023-08-02 |
Technophage, Investigação e Desenvolvimento em Biotecnologia, SA |
Antibacterial phage, phage peptides and methods of use thereof
|
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
|
AR083651A1
(es)
|
2010-10-21 |
2013-03-13 |
Galderma Sa |
Composiciones de brimonidina en gel y metodos de uso
|
|
CN107189997A
(zh)
|
2011-04-21 |
2017-09-22 |
洛克菲勒大学 |
用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
|
|
CA2834855C
(en)
*
|
2011-05-25 |
2020-12-29 |
Novaliq Gmbh |
Topical pharmaceutical composition based on semifluorinated alkanes
|
|
KR20140081783A
(ko)
*
|
2011-06-30 |
2014-07-01 |
알러간, 인코포레이티드 |
피부 질환을 치료하기 위한 레티노이드 국소 조성물 및 방법
|
|
AU2013235883B2
(en)
|
2012-03-19 |
2018-01-04 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. |
Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
|
|
ES2974663T3
(es)
|
2012-09-12 |
2024-07-01 |
Novaliq Gmbh |
Alcanos semifluorados para uso en la solubilización de meibomio
|
|
CA2883003C
(en)
|
2012-09-12 |
2021-11-16 |
Novaliq Gmbh |
Semifluorinated alkane compositions
|
|
DK2922528T3
(en)
|
2012-11-20 |
2017-09-18 |
Allergan Inc |
TOPICAL DAPSON AND DAPSON / ADAPALEN COMPOSITIONS AND PROCEDURES FOR USE THEREOF
|
|
US9012402B1
(en)
|
2014-06-11 |
2015-04-21 |
James Blanchard |
Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
|
|
WO2016019336A1
(en)
|
2014-07-31 |
2016-02-04 |
Allergan, Inc. |
Comparative efficacy and tolerability of dapsone 5% in adult versus adolescent females with acne vulgaris
|
|
DK3355990T3
(da)
|
2015-09-30 |
2019-09-16 |
Novaliq Gmbh |
Semifluorinerede forbindelser og disses sammensætninger
|
|
AU2016329261B2
(en)
|
2015-09-30 |
2020-05-07 |
Novaliq Gmbh |
Semifluorinated compounds for ophthalmic administration
|
|
RU2018118214A
(ru)
*
|
2015-11-04 |
2019-12-05 |
Аллерган, Инк. |
Способы лечения обыкновенной угревой сыпи с помощью местного применения композиций содержащих дапсон
|
|
PT3442480T
(pt)
|
2016-06-23 |
2019-12-23 |
Novaliq Gmbh |
Método de administração tópica
|
|
MX2019003363A
(es)
|
2016-09-22 |
2019-10-02 |
Novaliq Gmbh |
Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
|
|
AU2017329983B2
(en)
|
2016-09-23 |
2022-05-05 |
Novaliq Gmbh |
Ophthalmic compositions comprising ciclosporin
|
|
EP3612228B1
(en)
|
2017-04-21 |
2023-08-23 |
Dermaliq Therapeutics, Inc. |
Iodine compositions
|
|
US11278503B2
(en)
|
2017-05-12 |
2022-03-22 |
Novaliq Gmbh |
Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
|
|
US12011437B1
(en)
|
2017-06-07 |
2024-06-18 |
Arcutis Biotherapeutics, Inc. |
Roflumilast formulations with an improved pharmacokinetic profile
|
|
US20210161870A1
(en)
|
2017-06-07 |
2021-06-03 |
Arcutis Biotherapeutics, Inc. |
Roflumilast formulations with an improved pharmacokinetic profile
|
|
US20200155524A1
(en)
|
2018-11-16 |
2020-05-21 |
Arcutis, Inc. |
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
|
|
US11129818B2
(en)
|
2017-06-07 |
2021-09-28 |
Arcutis Biotherapeutics, Inc. |
Topical roflumilast formulation having improved delivery and plasma half life
|
|
US9895359B1
(en)
|
2017-06-07 |
2018-02-20 |
Arcutis, Inc. |
Inhibition of crystal growth of roflumilast
|
|
US12042487B2
(en)
|
2018-11-16 |
2024-07-23 |
Arcutis Biotherapeutics, Inc. |
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
|
|
US10821075B1
(en)
|
2017-07-12 |
2020-11-03 |
James Blanchard |
Compositions for topical application of a medicaments onto a mammalian body surface
|
|
JP2020535156A
(ja)
|
2017-09-27 |
2020-12-03 |
ノバリック ゲーエムベーハー |
眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
|
|
CN111182893A
(zh)
|
2017-10-04 |
2020-05-19 |
诺瓦利克有限责任公司 |
包含f6h8的眼用组合物
|
|
US20210062137A1
(en)
|
2017-12-22 |
2021-03-04 |
The Rockefeller University |
Recombinant pseudomonas aeruginosa lysins
|
|
JP7353292B2
(ja)
|
2018-03-02 |
2023-09-29 |
ノバリック ゲーエムベーハー |
ネビボロールを含む医薬組成物
|
|
KR20210044191A
(ko)
|
2018-06-04 |
2021-04-22 |
아큐티스, 인크. |
로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
|
|
ES2950878T3
(es)
|
2018-09-27 |
2023-10-16 |
Dermaliq Therapeutics Inc |
Formulación de protección solar de uso tópico
|
|
US12029757B2
(en)
|
2018-09-27 |
2024-07-09 |
Dermaliq Therapeutics, Inc. |
Lipid barrier repair
|
|
JP7500550B2
(ja)
|
2018-10-12 |
2024-06-17 |
ノバリック ゲーエムベーハー |
乾性眼疾患の治療のための眼科用組成物
|
|
US10945952B2
(en)
|
2019-03-14 |
2021-03-16 |
Crescita Therapeutics Inc. |
Rinse-off compositions and uses thereof for delivery of active agents
|
|
US12098372B2
(en)
|
2019-12-30 |
2024-09-24 |
Eligo Bioscience |
Microbiome modulation of a host by delivery of DNA payloads with minimized spread
|
|
US11746352B2
(en)
|
2019-12-30 |
2023-09-05 |
Eligo Bioscience |
Microbiome modulation of a host by delivery of DNA payloads with minimized spread
|
|
EP4096630A1
(en)
|
2020-01-31 |
2022-12-07 |
Arcutis Biotherapeutics, Inc. |
Topical roflumilast formulation having improved delivery and plasma half-life
|
|
US11617773B2
(en)
|
2020-04-08 |
2023-04-04 |
Eligo Bioscience |
Elimination of colonic bacterial driving lethal inflammatory cardiomyopathy
|
|
WO2021204967A1
(en)
|
2020-04-08 |
2021-10-14 |
Eligo Bioscience |
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
|
|
WO2021250284A1
(en)
|
2020-06-12 |
2021-12-16 |
Eligo Bioscience |
Specific decolonization of antibiotic resistant bacteria for prophylactic purposes
|
|
WO2022003209A1
(en)
|
2020-07-03 |
2022-01-06 |
Eligo Bioscience |
Method of containment of nucleic acid vectors introduced in a microbiome population
|
|
TW202227134A
(zh)
|
2020-09-11 |
2022-07-16 |
美商頂尖生物製劑公司 |
光動力療法組成物及其使用方法
|
|
WO2022144382A1
(en)
|
2020-12-30 |
2022-07-07 |
Eligo Bioscience |
Chimeric receptor binding proteins resistant to proteolytic degradation
|
|
WO2022169615A1
(en)
|
2021-02-05 |
2022-08-11 |
Arcutis Biotherapeutics, Inc. |
Roflumilast formulations with an improved pharmacokinetic profile
|
|
WO2023057598A1
(en)
|
2021-10-07 |
2023-04-13 |
Eligo Bioscience |
Methods involving bacterial strain replacement
|
|
WO2023057599A1
(en)
|
2021-10-07 |
2023-04-13 |
Eligo Bioscience |
Methods involving bacteroides strain replacement
|